Figure 1: Figure was adapted from Sharma et al. [3]. Distribution of various reported activating oncogenic mutations in a survey of 139 non-small-cell lung cancer (NSCLC)-derived cell lines. Also shown for all the activating mutations (except KRAS) are inhibitors (supplemented by the author) that selectively target the activated oncoproteins, yielding the most effective growth inhibition and/or apoptosis of cancer cell lines. There are currently no inhibitors that target oncogenic KRAS [3], but it has been reported that Sorafenib is the best treatment option for those lung cancer patients with KRAS mutations [2].